Inhibition of p53 protein aggregation as a cancer treatment strategy
- 25 November 2022
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 72, 102230
Abstract
No abstract availableKeywords
Funding Information
- Centre National de la Recherche Scientifique
- Australian Research Council
- Institut National de la Santé et de la Recherche Médicale
- Natural Sciences and Engineering Research Council of Canada (RGPIN-2019-06749)
- Ligue Contre le Cancer
This publication has 55 references indexed in Scilit:
- Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53Nature Communications, 2013
- Allele-Specific p53 Mutant ReactivationCancer Cell, 2012
- The Amyloid State of Proteins in Human DiseasesCell, 2012
- Misfolded proteins in Alzheimer's disease and type II diabetesChemical Society Reviews, 2011
- Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 TetramerJournal of Molecular Biology, 2011
- New insights into p53 activationCell Research, 2010
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drugProceedings of the National Academy of Sciences, 2008
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- p53 modulation of the DNA damage responseJournal of Cellular Biochemistry, 2006
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002